BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, Dillon JF, Forrest E, Fraser A, Gillespie R, Goldberg DJ, Kennedy N, Mcdonald S, Mcleod A, Mills PR, Morris J, Hayes P; on behalf of the Hepatitis C Clinical Database Monitoring Committee. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011;54:1547-58. [DOI: 10.1002/hep.24561] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Vergniol J, de Lédinghen V. HCV: Fibrosis Progression. Curr Hepatology Rep 2014;13:265-72. [DOI: 10.1007/s11901-014-0247-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, Laferl H, Stättermayer AF, Scherzer T, Strassl R, Holzmann H, Steindl-munda P, Ferenci P. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013;38:118-23. [DOI: 10.1111/apt.12350] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
3 Wang Y, Hou J. Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. Hepatol Int 2016;10:448-61. [DOI: 10.1007/s12072-015-9695-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 McPherson S, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, Hallsworth K, Campbell M. Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. BMJ Open Gastroenterol 2020;7:e000470. [PMID: 32847899 DOI: 10.1136/bmjgast-2020-000470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoove M, Wiktor SZ, Hutchinson S. Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. Eur J Epidemiol 2015;30:115-29. [PMID: 25385677 DOI: 10.1007/s10654-014-9958-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
6 Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol 2021;74:952-63. [PMID: 33276027 DOI: 10.1016/j.jhep.2020.11.040] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Leroy V, Riachi G, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-thoraval F, Nahon P, Marcellin P, Guyader D, Pol S, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J, Zarski J, Leroy V, Riachi G, Calès P, Péron J, Alric L, Bourlière M, Mathurin P, Blanc J, Abergel A, Serfaty L, Mallat A, Grangé J, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology 2017;152:142-156.e2. [DOI: 10.1053/j.gastro.2016.09.009] [Cited by in Crossref: 275] [Cited by in F6Publishing: 247] [Article Influence: 55.0] [Reference Citation Analysis]
8 Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol. 2013;11:1014-1020.e1-2. [PMID: 23602817 DOI: 10.1016/j.cgh.2013.03.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
9 Par G, Szereday L, Berki T, Palinkas L, Halasz M, Miseta A, Hegedus G, Szekeres-Bartho J, Vincze A, Hunyady B, Par A. Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin. PLoS One 2013;8:e67770. [PMID: 23874444 DOI: 10.1371/journal.pone.0067770] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
10 Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55 Suppl 1:S33-S42. [PMID: 22715212 DOI: 10.1093/cid/cis367] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 10.6] [Reference Citation Analysis]
11 Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018;44:143-60. [PMID: 28539069 DOI: 10.1080/1040841X.2017.1329277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
12 Serfaty L. Follow-up of patients with chronic hepatitis C and a sustained viral response. Liver Int. 2016;36 Suppl 1:67-71. [PMID: 26725900 DOI: 10.1111/liv.13016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
13 Hutchinson SJ, Dillon JF, Fox R, McDonald SA, Innes HA, Weir A, McLeod A, Aspinall EJ, Palmateer NE, Taylor A, Munro A, Valerio H, Brown G, Goldberg DJ. Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. Int J Drug Policy 2015;26:1041-9. [PMID: 26123893 DOI: 10.1016/j.drugpo.2015.05.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
14 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19. [PMID: 25596623 DOI: 10.1186/s12879-015-0748-8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 15.0] [Reference Citation Analysis]
15 O'Kelly M, Byrne D, Naughten E, Bergin C, Williams C. Opt-out testing for blood-borne viruses in primary care: a multicentre, prospective study. Br J Gen Pract 2016;66:e392-6. [PMID: 27114211 DOI: 10.3399/bjgp16X685225] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
16 Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 2014;161:546-53. [PMID: 25329202 DOI: 10.7326/M14-0602] [Cited by in Crossref: 65] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
17 Innes H, Goldberg D, Dillon J, Hutchinson SJ. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut 2015;64:1800-9. [DOI: 10.1136/gutjnl-2014-308166] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
18 Zahnd C, Salazar-Vizcaya L, Dufour JF, Müllhaupt B, Wandeler G, Kouyos R, Estill J, Bertisch B, Rauch A, Keiser O; Swiss HIV., Swiss Hepatitis C Cohort Studies. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. J Hepatol 2016;65:26-32. [PMID: 26921687 DOI: 10.1016/j.jhep.2016.02.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
19 Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clin Infect Dis. 2015;61:730-740. [PMID: 25987643 DOI: 10.1093/cid/civ396] [Cited by in Crossref: 184] [Cited by in F6Publishing: 167] [Article Influence: 26.3] [Reference Citation Analysis]
20 Chen EY, North CS, Fatunde O, Bernstein I, Salari S, Day B, Jain MK. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults. J Viral Hepat. 2013;20:708-714. [PMID: 24010645 DOI: 10.1111/jvh.12095] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
21 Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, Davidson BR, Burroughs AK. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2013;:CD003617. [PMID: 23440791 DOI: 10.1002/14651858.CD003617.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
22 Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley A, Bramley P, Hutchinson SJ. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol. 2017;66:19-27. [PMID: 27545496 DOI: 10.1016/j.jhep.2016.08.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
23 Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology. 2013;57:451-460. [PMID: 22961861 DOI: 10.1002/hep.26051] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
24 Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, Tsui JI. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014;109:62-70. [PMID: 24112091 DOI: 10.1111/add.12367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
25 Valerio H, Goldberg DJ, Lewsey J, Weir A, Allen S, Aspinall EJ, Barclay ST, Bramley P, Dillon JF, Fox R, Fraser A, Hayes PC, Innes H, Kennedy N, Mills PR, Stanley AJ, Hutchinson SJ. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. Drug Alcohol Depend 2015;154:125-31. [PMID: 26183402 DOI: 10.1016/j.drugalcdep.2015.06.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
26 Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). BMJ Open 2019;9:e029538. [PMID: 31551376 DOI: 10.1136/bmjopen-2019-029538] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
27 Alfaleh FZ, Alswat K, Helmy A, Al-hamoudi W, El-sharkawy M, Omar M, Shalaby A, Bedewi MA, Hadad Q, Ali SM, Alfaleh A, Abdo AA. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. Liver Int 2013;33:871-83. [PMID: 23490034 DOI: 10.1111/liv.12127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
28 Liu S, Barnett PG, Holodniy M, Lo J, Joyce VR, Gidwani R, Asch SM, Owens DK, Goldhaber-Fiebert JD. Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations. MDM Policy Pract 2016;1. [PMID: 29756049 DOI: 10.1177/2381468316671946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Cochrane Database Syst Rev. 2012;9:CD008516. [PMID: 22972122 DOI: 10.1002/14651858.cd008516.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, Diels J, Lawson A, Neal KR, Wiselka MJ. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat. 2014;21:208-215. [PMID: 24438682 DOI: 10.1111/jvh.12132] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
31 Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. 2015;62:355-364. [PMID: 25716707 DOI: 10.1002/hep.27766] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 11.0] [Reference Citation Analysis]
32 Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. 2014;6:4-15. [PMID: 24106239 DOI: 10.1002/emmm.201303131] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 8.8] [Reference Citation Analysis]
33 Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, Ngo Y, Thibault V, Mkada H, Charlotte F, Bismut FI, Deckmyn O, Benhamou Y, Valantin MA, Ratziu V, Katlama C; FibroFrance-GHPS group. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59:675-683. [PMID: 23712051 DOI: 10.1016/j.jhep.2013.05.015] [Cited by in Crossref: 102] [Cited by in F6Publishing: 98] [Article Influence: 11.3] [Reference Citation Analysis]
34 McCaughan GW. Is the end of chronic hepatitis C virus infection in sight? Med J Aust 2012;196:614. [PMID: 22676864 DOI: 10.5694/mja12.10586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Chou R, Dana T, Fu R, Zakher B, Wagner J, Ramirez S, Grusing S, Jou JH. Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020;Epub ahead of print. [PMID: 32119034 DOI: 10.1001/jama.2019.20788] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
36 Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, Ramsay ME, De Angelis D, Hickman M, Harris HE. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat 2016;23:631-43. [PMID: 27025238 DOI: 10.1111/jvh.12529] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
37 Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23-30. [PMID: 24726738 DOI: 10.1016/j.antiviral.2014.03.012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 10.3] [Reference Citation Analysis]
38 Zator ZA, Chung RT. After the cure: management of HCV after achievement of SVR. Curr HIV/AIDS Rep 2013;10:428-35. [PMID: 24218111 DOI: 10.1007/s11904-013-0181-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
39 McCaughan GW. New therapies against HCV: expected risks and challenges associated with their use in the liver transplant setting. J Hepatol 2012;57:1361-7. [PMID: 22885390 DOI: 10.1016/j.jhep.2012.07.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
40 Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-270. [PMID: 22056542 DOI: 10.7326/0003-4819-156-4-201202210-00378] [Cited by in Crossref: 221] [Cited by in F6Publishing: 219] [Article Influence: 20.1] [Reference Citation Analysis]
41 Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol 2017;17:46. [PMID: 28376711 DOI: 10.1186/s12876-017-0606-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
42 Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020;71:44-55. [PMID: 31222774 DOI: 10.1002/hep.30823] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 22.7] [Reference Citation Analysis]
43 Jordovic J, Bojovic K, Simonovic-Babic J, Gasic V, Kotur N, Zukic B, Vukovic M, Pavlovic S, Lazarevic I, Bekic I, Nikolic N, Uroševic A, Mitrovic N, Delic D. Significance of UGT1A1*28 Genotype in Patients with Advanced Liver Injury Caused By Chronic Hepatitis C. J Med Biochem 2019;38:45-52. [PMID: 30820183 DOI: 10.2478/jomb-2018-0015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
45 Vandenbulcke H, Moreno C, Colle I, Knebel JF, Francque S, Sersté T, George C, de Galocsy C, Laleman W, Delwaide J, Orlent H, Lasser L, Trépo E, Van Vlierberghe H, Michielsen P, van Gossum M, de Vos M, Marot A, Doerig C, Henrion J, Deltenre P. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 2016;65:543-51. [PMID: 27180899 DOI: 10.1016/j.jhep.2016.04.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
46 Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, Amin J, Goldberg DJ, Innes H, Law M, Walter SR, Krajden M, Dore GJ. Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment. Journal of Hepatology 2015;62:269-77. [DOI: 10.1016/j.jhep.2014.09.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
47 Durand F, Francoz C. The future of liver transplantation for viral hepatitis. Liver Int 2017;37:130-5. [DOI: 10.1111/liv.13310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]